CCO Treatment Updates
New Options for HCV Nonresponders: Navigating Emerging Data and Best Practices for Treatment-Experienced Patients
This Treatment Update is specifically designed for frontline providers, nurse practitioners, physician assistants, and others who treat patients who have been previously treated for HCV. It will provide program participants with the latest data and best practices on management approaches for these patients as well as a means to synthesize these strategies through Interactive Case Challenges.
Part 1 - Management of Previous HCV Treatment Nonresponders
Virtual Presentation
Management of HCV Nonresponders
|
|
|
 Join Ira M. Jacobson, MD, as he discusses treatment strategies for the optimal management of patients with chronic hepatitis C with previous nonresponse to antiviral therapy. Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify management strategies for persons who were previously treated with interferon-based and ribavirin therapy
- Discuss study results concerning the retreatment of HCV-infected persons previously nonresponsive to antiviral therapy
- Describe data concerning treatment approaches using novel agents in development for HCV-infected persons previously nonresponsive to antiviral therapy
|
Management of HCV Nonresponders
 |
|
Download and review key data selected by Ira Jacobson, MD on the retreatment of patients with a previous suboptimal response to HCV therapy. Use the slides in your own presentations!
Format: Microsoft PowerPoint (.ppt) | File size: 1,042 KB
|
Interactive Case Challenge
Treatment of a Genotype 1a Patient Not Achieving Full Virologic Suppression With Peginterferon/Ribavirin at 24 Weeks
- Maria H. Sjogren, MD, MPH, FACP
|
|
|
 Maria Sjogren, MD, discusses the treatment management options for patients not achieving HCV RNA suppression after 24 weeks of peginterferon alfa-2b/ribavirin. Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the types of responses an HCV-infected patient might achieve with standard peginterferon/ribavirin therapy
- Summarize the treatment options for partial responders to peginterferon/ribavirin
- Discuss the effects of baseline factors on future treatment strategies for nonresponders and partial responders
|
Part 2 - Optimizing and Individualizing HCV Retreatment (coming soon)
Virtual Presentation
Maintaining Patients on Treatment: Optimizing and Individualizing Retreatment for Success
|
|
|
Join Bruce R. Bacon, MD, as he discusses strategies for maintaining therapy in patients who are being retreated for hepatitis C Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss management strategies for optimizing retreatment success in patients with chronic HCV infection
- Explain individualized approaches to addressing modifiable factors associated with adherence in HCV treatment
- Describe data addressing the use of growth factors to sustain therapeutic dosing and duration in HCV treatment
|
Maintaining Patients on Treatment: Optimizing and Individualizing Retreatment for Success
 |
|
Download and review key data selected by Bruce R. Bacon, MD on optimizing and individualizing retreatment with available agents in patients with a previous suboptimal response to HCV therapy. Use the slides in your own presentations!
Format: Microsoft PowerPoint (.ppt) | File size: 1,049 KB
|
Interactive Case Challenge
Optimizing Treatment Success of a Second HCV Regimen in a Patient With Unsuccessful Initial Treatment With Peginterferon alfa-2a and Ribavirin
|
|
|
Robert G. Gish, MD, discusses management strategies for a patient predisposed to anemia and depression. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss treatment regimen options for patients with previous unsuccessful HCV treatment
- Recount strategies to control ribavirin-induced anemia
- Summarize alternative treatment approaches for patients with suboptimal on-treatment HCV response
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|
|